Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.